logo
Transcript: U.K. Ambassador Peter Mandelson on "Face the Nation with Margaret Brennan," May 11, 2025

Transcript: U.K. Ambassador Peter Mandelson on "Face the Nation with Margaret Brennan," May 11, 2025

CBS News11-05-2025
The following is the transcript of an interview with Peter Mandelson, United Kingdom's Ambassador to the United States, that aired on "Face the Nation with Margaret Brennan" on May 11, 2025.
ED O'KEEFE: We're delighted to turn now to the United Kingdom's Ambassador to the United States, Peter Mandelson, who's here making his Face the Nation debut. Ambassador, thank you for being here.
AMB. PETER MANDELSON: It's great to be here, and Happy Mother's Day to all those moms out there.
ED O'KEEFE: Indeed, to all of them, wherever they are. I wanted to start with the fact that the United States and the United Kingdom have now announced a framework, a framework for a trade deal that covers all sorts of things, steel, aluminum, cars, beef. You're scrapping a 20 percent tariff on U.S. beef, you're raising a quota on its imports. Do you have any sense of how soon this deal is going to be finalized, and do you trust that the United States is going to hold up its end of the bargain?
AMB. MANDELSON: Oh, yes, we regard it as finalized. A deal is a deal, and I have absolutely no doubt that the President and his colleagues, Secretary Lutnick and USTR Jamieson Greer, having said they would do a deal, have been true to their word. They delivered this deal, and I have absolute confidence that they'll see it through. And it reflects the confid- the sort of amazing, confident relationship between our two countries, and the cordial relationship personally between the president and the prime minister and now we can build on it. I mean, we can look at- look to other trade barriers that we can bring down so as to create more jobs in the United States, and also something very close to my heart, I want to see us build a close U.S.-U.K. technology partnership. To invest, to build future industries in both our countries, which are science based and driven by technology. That would be a great gain--
ED O'KEEFE: --and it's not part of this deal--
AMB. MANDELSON: -- oh yes-
ED O'KEEFE: –So it requires another round.
AMB. MANDELSON: No, no, it's- it's featured in the deal, but it requires now work right to design it.
ED O'KEEFE: My read in the British press, I'm going to pin this on the British press, is that you've accepted a worse deal than the U.K. had before just to get out from the shadow of the tariff threat. Is it that you guys perhaps rushed to be first before all other countries?
AMB. MANDELSON: I don't- I don't- literally don't understand the logic of that. The fact is that-
ED O'KEEFE: --Well, you're paying more tariff than you were before, right? That's part of it.
AMB. MANDELSON: Well, in some cases, but in other cases, we're not. I mean, in some cases, we're down to zero. So- and in other cases, for example, in autos, we've got absolutely secure quotas for exports to the United States. So it's a good deal, and I'm very pleased that we've achieved it, but now we have to build on it.
ED O'KEEFE: The other tariff thing that came up this week that has the potential to adversely affect the British economy is the idea of a 100 percent tariff on any movies produced outside the United States. Have you discussed that year with the administration? Do you have any sense of how that could adversely affect the British film industry?
AMB. MANDELSON: Well, we touched on it, but this is American film production taking place in Britain, and we want to protect the American film industry and tariffs, if you can put a tariff on a film, is not going to do that. But whether it be in respect of films or pharmaceuticals that may be coming down the track towards us, we have an agreement in this deal that British interests will be protected alongside those of the United States.
ED O'KEEFE: I want to turn to Russia and Ukraine, because that was a great focus of your Prime Minister this weekend. He said, after the announcement of the proposed ceasefire this weekend, that if Putin, quote, "is serious about peace, he has a chance to show it," but he's basically ignored the ceasefire proposal and is now once again, calling for one-on-one talks. Do you- is the assessment of your government that Russia is at all serious about this?
AMB. MANDELSON: Look at face value it's constructive that he's offered direct talks for Putin with- with the Ukrainians. But then when you look at the small print, you see what he- you see that he wants these talks so as to call into question the very existence of Ukraine as a free, democratic and sovereign nation. And in the meantime, overnight, this weekend, we've had Russian munitions and drones raining down on Ukraine and killing Ukrainian people. It doesn't seem serious to us, and we're very glad that the Ukrainians have embraced this ceasefire, as the President asked them to do. But the truth is that it looks as if President Putin is engaging in brinkmanship with President Trump, and certainly, as far as we're concerned in Britain, we only want one president to prevail in this standoff, and that's President Trump, not President Putin, and that may require, therefore, additional pressure being mounted on Russia in order to bring them to the negotiating table.
ED O'KEEFE: And I'm curious, you've been around the president in recent days. He's been clearly charmed by you, and you've been talking to the administration about a host of things. Is it your sense that he and his administration has, in essence, turned the corner on the Ukraine-Russia conflict in the last few weeks, siding more now, clearly with Ukraine?
AMB. MANDELSON: I think we are at a defining moment in this conflict, this war between- that Russia has launched on Ukraine. And that's why I think that the administration now needs to consider how it's going to pursue its goal of peace. That goal can only be realized if Russia, Putin matches what Zelensky and Ukrainians have offered, which is a 30-day ceasefire during which proper negotiations can take place. That's what we need to see.
ED O'KEEFE: Does the United States need to pass a new round of sanctions against Russia if they don't follow through in the next few days?
AMB. MANDELSON: Well, Senator Lindsey Graham has a bill–
ED O'KEEFE: He does, yes.
AMB. MANDELSON: –with his colleagues up on the- on the Hill, and I think the administration will want to judge the timeliness, appropriateness of backing that bill.
ED O'KEEFE: All right. Ambassador Peter Mandelson, thank you so much for stopping by. Don't be a stranger. Come again.
AMB. MANDELSON: I'd love to.
ED O'KEEFE: All right, thank you. We'll be back in a moment. Stay with us.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US EPA moves to approve dicamba weedkiller use on cotton, soybeans
US EPA moves to approve dicamba weedkiller use on cotton, soybeans

Yahoo

time8 minutes ago

  • Yahoo

US EPA moves to approve dicamba weedkiller use on cotton, soybeans

By Leah Douglas and Tom Polansek WASHINGTON (Reuters) -The U.S. Environmental Protection Agency on Wednesday proposed approvals for three products containing the weedkiller dicamba, whose use was halted by a federal court in 2024, arguing it does not pose a significant human health or environmental risk. Cotton and soybean farmers had sprayed dicamba on crops that were genetically engineered to resist the herbicide, which controls tough weeds. Environmental groups have criticized the chemical because it can drift from where it is sprayed and damage neighboring plants. A 2024 U.S. District Court ruling found the EPA previously violated public input procedures in its approval of three dicamba products, and vacated the product registrations. As a result, farmers were unable to spray dicamba on crops this year. The EPA has received applications from Bayer AG, BASF and Syngenta for new approvals, the agency said in regulatory documents. Bayer, which sold the dicamba herbicide XtendiMax, said it was pleased the EPA opened a public comment period on its proposal to approve dicamba usage. "We are confident that low-volatility dicamba herbicides, when used according to the label, can be used safely and successfully on-target," Bayer said. BASF said it would work with regulators to ensure farmers can use dicamba. Syngenta did not immediately respond to a request for comment. An EPA review found no risk to human health from the products, but some risk to certain plants, it said in a release. To mitigate that risk, the agency is proposing restrictions on how much of the chemical can be applied and when, the release said. The top pesticides official at the EPA's Office of Chemical Safety and Pollution Prevention, Kyle Kunkler, previously worked as a lobbyist for the American Soybean Association, which has supported allowing farmers to spray dicamba on soybeans. The association said it was reviewing the EPA's proposal and that dicamba is a critical tool for farmers.

Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause
Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause

Yahoo

time8 minutes ago

  • Yahoo

Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause

Sarepta Therapeutics' (SRPT) stock has been hammered in the past week after the company was forced to pause shipments of its top-selling Duchenne muscular dystrophy (DMD) therapy Elevidys — throwing the future of the company into question. Elevidys netted $821 million of the company's $1.78 billion in 2024 revenue and contributed to more than 50% of the company's $513 million in second quarter revenue this year. It's the company's top-selling product. It's why seven analysts have downgraded the stock since Friday, including Bank of America's Tazeen Ahmad on Wednesday. Ahmad downgraded the stock to Underperform and revised the firm's price target to $10 from $20. The stock is currently trading at $13.90 per share and closed down more than 2% on Wednesday. Sarepta "has requested a meeting with FDA and might have more visibility on length of the pause once FDA responds to their submission for a revised label," Ahmad wrote in a note to clients. "In short, we think this could impact the Elevidys brand further, limiting uptake following highly focused media attention as well as a renewed chance of Elevidys being removed from the US market." Leerink Partners downgraded the stock last week from Outperform to Market Perform. Analyst Joseph Schwartz wrote in a note to clients on Monday that how long the pause lasts is important for future modeling. "This decision is also roughly aligned with our published SRPT model, which assumes a significant slowing of sales in the third quarter, zero sales in the fourth quarter, and a resumption of shipments in early 2026," Schwartz wrote. "We lack visibility into how long this pause may last, or what the intermediate scenarios are from here (e.g., a narrower approval)." The stock now has five Buy, 17 Hold, and four Sell ratings. Domino effect The technology to deliver the therapy in Elevidys is at the center of the issue facing the company. A 51-year-old, late-stage patient in a phase 1 trial of a different muscular dystrophy therapy, known only by its trial name, SRP-9004, died from liver toxicity last month, but Sarepta failed to disclose the death — even as it announced it was discontinuing the trial as part of a restructuring last week. That began the domino effect of downgrades and the stock sell-off as analysts questioned why the company had kept quiet. On a call with investors Friday, CEO Doug Ingram defended his reasoning for not mentioning it. "We did not discuss this matter in our call on Wednesday because it was neither material nor central to the topics at hand on Wednesday," Ingram said. In a note following the call, Leerink's Schwartz wrote, "Is This Material?!? All Credibility Lost." It's the third death linked to a gene therapy from the company this year and a reason why the FDA previously required the company to add new warning labels to Elevidys, which is part of the pause in shipments currently. But now, the company's future is in flux as its revenue stream has been paused for an undetermined amount of time. Jefferies analyst Andrew Tsai, one of the few who has maintained a Buy rating, said the company could defend the therapy as sicker and older patients have been more negatively impacted, while younger patients who are still able to move independently have benefited. "Prior to the third death, SRPT's internal stress tests suggested the DMD franchise could 'floor' at $1.4B annually into 2027, including $500M+ for Elevidys in ambulatory," Tsai wrote in a note to clients Sunday. "For Elevidys, one can point to how the deaths have occurred only in older patients." "More cost reductions is possible too," Tsai noted of how Sarepta could end up handling the hit. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices

Digital Turbine to Host Fiscal 2026 First Quarter Financial Results Conference Call on August 5, 2025, at 4:30p ET
Digital Turbine to Host Fiscal 2026 First Quarter Financial Results Conference Call on August 5, 2025, at 4:30p ET

Yahoo

time8 minutes ago

  • Yahoo

Digital Turbine to Host Fiscal 2026 First Quarter Financial Results Conference Call on August 5, 2025, at 4:30p ET

AUSTIN, Texas, July 23, 2025 /PRNewswire/ -- Digital Turbine, Inc. (Nasdaq: APPS), a global mobile platform company, announced it will host a conference call and webcast to discuss its fiscal 2026 first quarter financial results and operating progress on Tuesday, August 5th, at 4:30pm ET/1:30pm PT. The call, hosted by Digital Turbine's Chief Executive Officer Bill Stone and Chief Financial Officer Steve Lasher, can be accessed via webcast link: The call can also be accessed by dialing 888-317-6003 in the United States (or 412-317-6061 from international locations) and entering access code 6968884. A live and archived webcast of the call can be accessed via the Investor Relations section of Digital Turbine's website. The webcast will be archived for a period of one year. For those unable to join the live call, a playback will be available through August 12th, 2025. The replay can be accessed by dialing 877-344-7529 in the United States or 412-317-0088 from international locations, passcode 2487796. About Digital Turbine Digital Turbine is the driving force behind superior mobile experiences for consumers and results for the world's leading mobile operators, advertisers and publishers. Our platform uniquely simplifies our partners' ability to drive end-to-end recognition, acquisition and monetization - connecting them to more consumers, in more ways, on more devices. Digital Turbine is headquartered in North America, with offices around the world. For additional information visit Follow Digital Turbine: Twitter Facebook LinkedIn Digital TurbineInvestor Relations Contact: Brian BartholomewDigital View original content to download multimedia: SOURCE Digital Turbine, Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store